EE05497B1 - Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha - Google Patents

Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha

Info

Publication number
EE05497B1
EE05497B1 EEP200100472A EEP200100472A EE05497B1 EE 05497 B1 EE05497 B1 EE 05497B1 EE P200100472 A EEP200100472 A EE P200100472A EE P200100472 A EEP200100472 A EE P200100472A EE 05497 B1 EE05497 B1 EE 05497B1
Authority
EE
Estonia
Prior art keywords
polypeptide
cram
polynucleotide
antibody
soluble
Prior art date
Application number
EEP200100472A
Other languages
English (en)
Estonian (et)
Inventor
Albert Imhof Beat
Aurrand-Lions Michel
Original Assignee
Rmf Dictagene S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rmf Dictagene S.A. filed Critical Rmf Dictagene S.A.
Publication of EE200100472A publication Critical patent/EE200100472A/xx
Publication of EE05497B1 publication Critical patent/EE05497B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
EEP200100472A 1999-03-11 2000-03-13 Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha EE05497B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200746 1999-03-11
PCT/EP2000/002219 WO2000053749A2 (en) 1999-03-11 2000-03-13 Vascular adhesion molecules and modulation of their function

Publications (2)

Publication Number Publication Date
EE200100472A EE200100472A (et) 2002-12-16
EE05497B1 true EE05497B1 (et) 2011-12-15

Family

ID=8239973

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100472A EE05497B1 (et) 1999-03-11 2000-03-13 Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha

Country Status (23)

Country Link
US (3) US7393651B2 (cs)
EP (2) EP2292761A1 (cs)
JP (2) JP4836329B2 (cs)
CN (2) CN1637019A (cs)
AT (1) ATE500328T1 (cs)
AU (1) AU782139B2 (cs)
BR (1) BR0008915A (cs)
CA (1) CA2362896C (cs)
CZ (1) CZ303128B6 (cs)
DE (1) DE60045681D1 (cs)
EE (1) EE05497B1 (cs)
ES (1) ES2361905T3 (cs)
HK (1) HK1044169A1 (cs)
HU (1) HU229376B1 (cs)
IL (1) IL145310A0 (cs)
IS (1) IS2819B (cs)
MX (1) MXPA01009110A (cs)
NO (1) NO333085B1 (cs)
NZ (1) NZ514091A (cs)
PL (1) PL207994B1 (cs)
RU (1) RU2244748C2 (cs)
WO (1) WO2000053749A2 (cs)
ZA (1) ZA200107283B (cs)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
CZ303128B6 (cs) * 1999-03-11 2012-04-18 Laboratoires Serono Sa Adhezní molekula 1 regulovaná konfluencí CRAM-1, její kódující nukleová kyselina, protilátky a použití
GB0100750D0 (en) * 2001-01-11 2001-02-21 Inpharmatica Ltd Novel proteins
WO2003006673A2 (en) * 2001-07-11 2003-01-23 Texas Biotechnology Corporation A nucleic acid encoding a human junctional adhesion protein (jam3)
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (en) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
WO2007056227A2 (en) 2005-11-04 2007-05-18 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
RU2464030C2 (ru) * 2006-05-26 2012-10-20 Регадо Байосайенсиз, Инк. Введение противосвертывающей системы reg1
CA2663243A1 (en) 2006-09-28 2008-04-03 Merck Serono S.A. Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use
PL2907827T3 (pl) 2006-11-02 2019-03-29 Genentech, Inc. Humanizowane przeciwciała przeciw czynnikowi D i ich zastosowanie
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
LT2190991T (lt) * 2007-08-06 2020-02-10 Noxxon Pharma Ag Sdf-1 surišančios nukleorūgštys ir jų panaudojimas
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
CA2944712A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053753A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
WO2000036102A2 (en) * 1998-12-16 2000-06-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030170864A1 (en) * 2000-05-30 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
WO1998040483A2 (en) * 1997-03-14 1998-09-17 Human Genome Sciences, Inc. 28 human secreted proteins
EP0970111A2 (en) * 1997-03-21 2000-01-12 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
DK1000149T3 (da) 1997-08-01 2007-09-10 Serono Genetics Inst Sa 5'-EST'ere til udskilte proteiner identificeret fra hjernevæv
US20030092002A1 (en) * 1997-09-17 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1002864A1 (en) * 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
CZ303128B6 (cs) * 1999-03-11 2012-04-18 Laboratoires Serono Sa Adhezní molekula 1 regulovaná konfluencí CRAM-1, její kódující nukleová kyselina, protilátky a použití
EP1533617A1 (en) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
US7642341B2 (en) * 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer

Also Published As

Publication number Publication date
CA2362896A1 (en) 2000-09-14
ZA200107283B (en) 2002-12-24
CZ20013267A3 (cs) 2002-02-13
US7393651B2 (en) 2008-07-01
HUP0200606A2 (en) 2002-06-29
EE200100472A (et) 2002-12-16
CN100469878C (zh) 2009-03-18
CN1355843A (zh) 2002-06-26
HU229376B1 (en) 2013-11-28
US20100267649A1 (en) 2010-10-21
EP1163337B1 (en) 2011-03-02
BR0008915A (pt) 2002-04-09
NO20014417L (no) 2001-11-12
CN1637019A (zh) 2005-07-13
US7670826B2 (en) 2010-03-02
WO2000053749A3 (en) 2000-12-14
JP2010233572A (ja) 2010-10-21
MXPA01009110A (es) 2002-08-20
ATE500328T1 (de) 2011-03-15
AU4105100A (en) 2000-09-28
JP2002537837A (ja) 2002-11-12
HUP0200606A3 (en) 2004-11-29
EP2292761A1 (en) 2011-03-09
NZ514091A (en) 2004-01-30
IL145310A0 (en) 2003-01-12
AU782139B2 (en) 2005-07-07
US20080274970A1 (en) 2008-11-06
ES2361905T3 (es) 2011-06-24
EP1163337A2 (en) 2001-12-19
NO333085B1 (no) 2013-02-25
RU2244748C2 (ru) 2005-01-20
NO20014417D0 (no) 2001-09-11
IS2819B (is) 2012-12-15
PL350417A1 (en) 2002-12-16
DE60045681D1 (de) 2011-04-14
HK1044169A1 (en) 2002-10-11
JP4836329B2 (ja) 2011-12-14
US8143056B2 (en) 2012-03-27
CZ303128B6 (cs) 2012-04-18
CA2362896C (en) 2012-07-31
US20050266426A1 (en) 2005-12-01
IS6072A (is) 2001-09-10
WO2000053749A2 (en) 2000-09-14
PL207994B1 (pl) 2011-02-28

Similar Documents

Publication Publication Date Title
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
ATE255902T1 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv- verwandten krankheiten
TR200202253T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
ATE431359T1 (de) Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
ATE106943T1 (de) Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie.
ATE132197T1 (de) Monoklonale antikörper
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
ATE115409T1 (de) Glykoprotein-hormonrezeptor-moleküle.
NO993653D0 (no) Fremgangsmåte for diagnose, prognose og behandling av glaukom og relaterte sykdommer
ATE301712T1 (de) Z2-19a, ein menschliches homolog von dem protein 2-19
ES2061566T3 (es) Anticuerpos monoclonales contra la proteina e7 del papilomavirus humano tipo 16, procedimiento para su preparacion, asi como su empleo.
TR200000416T2 (tr) Neisseria loctoferrin bağlayıcı protein.
ATE308616T1 (de) Rantes mutanten und deren therapeutische verwendungen
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
DE69836278D1 (de) Allele formen von menschlichem stat3
BR0007816A (pt) Fator de estimulação óssea
DE3777359D1 (de) Aminosaeuresequenz des menschlichen alpha 2-plasmininhibitors und cdns sowie diese aminosaeuresequenz codierende genomische dns.
NO940797L (no) Reseptorderivater som har bindingseter for human-rhinovirus

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HE1A Change of address
MM4A Lapsed by not paying the annual fees

Effective date: 20180313